Annual Drug Patent Expirations for BYDUREON
Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. It is available from one supplier. There are thirty patents protecting this drug.
Drug patent litigation for BYDUREON.
This drug has four hundred and thirty-seven patent family members in forty-eight countries.
The generic ingredient in BYDUREON is exenatide. One supplier is listed for this compound. Additional details are available on the exenatide profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
